Pluripotent stem cell-derived megakaryocytes and platelets
Assigneec/o Stratus Therapeutics, Inc.
InventorDhvanit Shah
Life of this patent
Estimating the term…
Abstract
The present disclosure provides for efficient ex vivo processes for generating megakaryocytes and/or platelets from human induced pluripotent stem cells (iPSCs). Cells and platelets generated according to the disclosure in various embodiments are functional and/or more closely resemble the corresponding lineage isolated from peripheral blood, bone marrow, or other tissues. The present invention in some aspects provides isolated cells/platelets and compositions produced by the methods disclosed herein, as well as methods for therapy.
Claims28
A method for preparing a cell population comprising megakaryocytes, the method comprising:
- enriching CD34+ cells from a population of differentiated pluripotent stem cells (PSCs) to prepare a CD34+-enriched population;
- inducing endothelial-to-hematopoietic transition (EHT) of the CD34+-enriched population to prepare a population comprising hematopoietic stem cells (HSCs) and/or hematopoietic stem progenitor cells (HSPCs), and optionally harvesting cells undergoing endothelial-to-hematopoietic transition;
- differentiating the HSC population into megakaryocytes and optionally forming platelets.
(canceled)
(canceled)
(canceled)
13-14. (canceled)
The method of claim 14, wherein CD34+ cells are harvested from culture undergoing endothelial-to-hematopoietic transition, including harvesting of CD34+ floater and/or adherent cells.
17-21. (canceled)
24-25. (canceled)
27-32. (canceled)
(canceled)
Dependencies are inferred from the claim text.